Full-dose chemotherapy in early stage breast cancer regardless of absolute neutrophil count and without G-CSF does not increase chemotherapy-induced febrile neutropenia

被引:8
|
作者
Chiarotto, James A. [1 ]
Dranitsaris, George [1 ]
机构
[1] Rouge Valley Hlth Syst, Oncol Program, Dept Med, Toronto, ON M1E 5E9, Canada
关键词
Day-before bloodwork; Neutropenia; Febrile neutropenia; Breast cancer; Chemotherapy; HODGKIN LYMPHOMA; RISK; ADRIAMYCIN; INTENSITY; VINBLASTINE; DACARBAZINE; PREDICTORS; BLEOMYCIN; ABVD;
D O I
10.1007/s00520-013-1851-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Does giving full-dose adjuvant chemotherapy to patients with early stage breast cancer (ESBC) regardless of the day-before absolute neutrophil count (ANC) lead to an increased incidence of chemotherapy-induced febrile neutropenia (CIFN)? What factors may predispose patients to CIFN? This was a retrospective chart review conducted on all patients receiving adjuvant chemotherapy for ESBC at a mid-sized community hospital in Toronto, Ontario, Canada between September 2005 and August 2011. Day-before CBC data were collected along with other patient characteristics. CIFN was confirmed by hospital records. One hundred fifty-four patients met the inclusion criteria. Overall, 830 cycles of chemotherapy were analyzed. Univariate and multivariate logistic regression analyses were used to identify risk factors for CIFN. Twenty-two episodes of CIFN were observed. There was no significant difference in day-before ANC between patients who developed CIFN relative to those who did not. The day-before ANC was < 1.5 x 10(9)/L for 88 cycles of chemotherapy. ANC analyzed as a continuous variable showed that the odds ratio (OR) for CIFN was 0.97 (95 % CI 0.82-1.13, p = NS). The pseudo R (2) statistic, which is a measure of variability accounted for by a regression model, was only 0.0008, indicating that ANC explained less than 1 % of the variability in the risk of CIFN. The most significant predictor of CIFN was the chemotherapy regimen, with docetaxel (Taxotere)/cyclophosphamide demonstrating the highest risk (OR 7.1, 95 % CI 1.4-34.9, p = 0.016). Full-dose adjuvant chemotherapy may be given to patients with ESBC regardless of the day-before ANC, without significantly increasing the risk of CIFN. The chemotherapy regimen is the most significant predictor for CIFN.
引用
收藏
页码:2727 / 2731
页数:5
相关论文
共 50 条
  • [41] Serum selenium measurements in women with early-stage breast cancer with and without chemotherapy-induced ovarian failure
    Smith, AM
    Breedlove, HA
    Shapiro, CL
    Burk, RF
    Hill, KE
    FASEB JOURNAL, 2004, 18 (05): : A917 - A917
  • [42] A comparison of eflapegrastim to pegfilgrastim in the management of chemotherapy-induced neutropenia in patients with early-stage breast cancer undergoing cytotoxic chemotherapy (RECOVER): A Phase 3 study
    Cobb, Patrick Wayne
    Moon, Yong Wha
    Mezei, Klara
    Lang, Istvan
    Bhat, Gajanan
    Chawla, Shanta
    Hasal, Steven J.
    Schwartzberg, Lee S.
    CANCER MEDICINE, 2020, 9 (17): : 6234 - 6243
  • [43] Randomized comparison of antibiotics alone and with granulocyte colony-stimulating factor (G-CSF) in children with chemotherapy-induced febrile neutropenia: A report from the Children's Oncology Group
    Ozkaynak, MF
    Krailo, M
    Chen, N
    Feusner, J
    PEDIATRIC RESEARCH, 2004, 55 (04) : 311A - 311A
  • [44] The relationship of relative dose intensity and supportive care to febrile neutropenia rates in patients with early stage breast cancer receiving chemotherapy: a prospective cohort study of chemotherapy associated toxicity
    Culakova, E.
    Poniewierski, M. S.
    Wogu, A. F.
    Kuderer, N. M.
    Crawford, J.
    Dale, D. C.
    Lyman, G. H.
    CANCER RESEARCH, 2012, 72
  • [45] The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis
    Tran Do
    Rohan Medhekar
    Raksha Bhat
    Hua Chen
    Polly Niravath
    Meghana V. Trivedi
    Breast Cancer Research and Treatment, 2015, 153 : 591 - 597
  • [46] The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the adjuvant docetaxel and cyclophosphamide in patients with early-stage breast cancer: A meta-analysis.
    Tran Do
    Niravath, Polly Ann
    Trivedi, Meghana
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis
    Do, Tran
    Medhekar, Rohan
    Bhat, Raksha
    Chen, Hua
    Niravath, Polly
    Trivedi, Meghana V.
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 153 (03) : 591 - 597
  • [49] TAC (docetaxel, doxorubicin, and cyclophosphamide) adjuvant chemotherapy supported by G-CSF without dose-reduction in node-positive breast cancer
    Suh, Y.
    Oh, S.
    Song, B.
    Jung, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] Randomized phase 3 study of a novel, long-acting G-CSF (SPI-2012) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study)
    Schwartzberg, L.
    Vacirca, J. L.
    Hager, S. J.
    Adoo, C. S.
    Ibrahim, E. N.
    Bhat, G.
    Choi, M. R.
    Allen, L. F.
    Tedesco, K. L.
    Agajanian, R.
    CANCER RESEARCH, 2016, 76